Renal Impairment, Cardiovascular Disease, and the Short-Term Efficacy and Safety of PCSK9 Targeted by Inclisiran

Affiliations

¹ Department of Cardiology, Leiden University Medical Center, The Netherlands. Electronic address: l.e.zijlstra@lumc.nl.
² Department of Cardiology and the Department of Gerontology and Geriatrics, Leiden University Medical Center, The Netherlands.
³ Department of Gerontology and Geriatrics, Leiden University Medical Center, Institute for Evidence-Based Medicine in Old Age (IEMO), The Netherlands.
⁴ Department of Nephrology, Leiden University Medical Center, The Netherlands; Department of Internal Medicine, Haga Hospital, The Hague, The Netherlands.
⁵ Department of Cardiology, Leiden University Medical Center, The Netherlands.

Editorial

Laurien E Zijlstra et al. Mayo Clin Proc. 2020 Jan.

. 2020 Jan;95(1):12-14.

doi: 10.1016/j.mayocp.2019.11.010.

¹ Department of Cardiology, Leiden University Medical Center, The Netherlands. Electronic address: l.e.zijlstra@lumc.nl.
² Department of Cardiology and the Department of Gerontology and Geriatrics, Leiden University Medical Center, The Netherlands.
³ Department of Gerontology and Geriatrics, Leiden University Medical Center, Institute for Evidence-Based Medicine in Old Age (IEMO), The Netherlands.
⁴ Department of Nephrology, Leiden University Medical Center, The Netherlands; Department of Internal Medicine, Haga Hospital, The Hague, The Netherlands.
⁵ Department of Cardiology, Leiden University Medical Center, The Netherlands.

No abstract available

Comment on

Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies.
Wright RS, Collins MG, Stoekenbroek RM, Robson R, Wijngaard PLJ, Landmesser U, Leiter LA, Kastelein JJP, Ray KK, Kallend D. Wright RS, et al. Mayo Clin Proc. 2020 Jan;95(1):77-89. doi: 10.1016/j.mayocp.2019.08.021. Epub 2019 Oct 17. Mayo Clin Proc. 2020. PMID: 31630870 Clinical Trial.